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Background: Hemodilutional anemia during cardiopulmonary bypass can lead to
inadequate oxygen delivery and, consequently, to ischemic organ injury. In adult
bypass, the nadir hematocrit can vary widely with body size and prebypass hemat-
ocrit variations, yet its effects on perioperative organ dysfunction and patient
outcomes remain largely unknown.
Methods: To elucidate these effects, we retrospectively analyzed operative results
and resource utilization data from 5000 consecutive cardiac operations with cardio-
pulmonary bypass performed on adults (1994 to 2000). Rolling decile groups (500
patients each; 75% overlapping) of increasing lowest hematocrit values were used
to characterize hemodilution-outcome relationships. Intermediate-term (0 to 6
years) survival was assessed for coronary artery bypass patients (n  3800) via
Kaplan-Meier analysis in quintile subgroups based on lowest hematocrit. Multivar-
iate logistic regression (operative mortality and morbidity) and Cox proportional
hazard model (0- to 6-year mortality) analyses were used to determine independent
predictors of poor outcomes.
Results: Stroke, myocardial infarction, low cardiac output, cardiac arrest, renal
failure, prolonged ventilation, pulmonary edema, reoperation due to bleeding,
sepsis, and multiorgan failure were all significantly and systematically increased as
lowest hematocrit value decreased below 22%. Consequently, intensive care re-
quirements, hospital stays, operative costs, and operative deaths were also signifi-
cantly greater as a function of hemodilution severity. Longer-term survival was
improved systematically for increasing lowest hematocrit coronary artery bypass
grafting quintiles; for example, 6-year survival was 80.5% and 92.3% for quintiles
I (lowest hematocrit 16.1%) and V (lowest hematocrit 27.5%). The continuous
variable lowest hematocrit was an independent predictor of (1) operative mortality,
(2) prolonged cardiovascular intensive case (2 days) and postoperative hospital
(8 days) stays, and (3) worse 0- to 6-year survival.
Conclusions: Increased hemodilution severity during cardiopulmonary bypass was
associated with worse perioperative vital organ dysfunction/morbidity and increased
resource use, as well as greater short- and intermediate-term mortality. We speculate
that these results derive from inadequate oxygen delivery causing ischemic and/or
inflammatory vital organ injury, as recently demonstrated intravitally in cerebral
tissues. Although this analysis of a large observational study offers evidence linking
low on-pump hematocrit values to these adverse outcomes, prospective randomized
trials are needed (1) to establish whether a causal effect of hemodilution on poor
outcomes actually exists and (2) to test the potential efficacy of maintaining
on-pump hematocrit above 22% for improving outcomes of cardiopulmonary by-
pass.
From Cardiovascular Surgery,a St Vincent
Mercy Medical Center, Toledo, Ohio; Saint
Luke’s Hospital,b Maumee, Ohio; and the
Department of Surgery,c Medical College
of Ohio, Toledo, Ohio.
Received for publication Feb 12, 2002; re-
vision requested May 24, 2002; revisions
received Aug 21, 2002; accepted for publi-
cation Aug 26, 2002.
Address for reprints: Robert H. Habib,
PhD, Director, Cardiopulmonary Research,
St Vincent Mercy Medical Center, 2213
Cherry St, ACC Building, Suite 309, Toledo,
OH 43608 (E-mail: Robert_Habib@mhsnr.
org).
J Thorac Cardiovasc Surg 2003;125:
1438-50
Copyright © 2003 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2003 $30.00  0
doi:10.1016/S0022-5223(02)125:1438-50
Habib et al Cardiopulmonary Support and Physiology
1438 The Journal of Thoracic and Cardiovascular Surgery ● June 2003
CPS
The Boston group1 headed by Jonas recentlydemonstrated, in an intravital animal model,that perfusion of the cerebral microcircula-tion is not impaired by high hematocrit value(30%) during cardiopulmonary bypass(CPB) compared with moderate (20%) or
low (10%) hematocrit value. They also reported evidence of
increasingly inadequate cerebral tissue oxygenation and
greater white cell–endothelial activation as hematocrit val-
ues during CPB decreased.1 Finally, the authors proposed
that their intravital results of increased ischemia and inflam-
matory tissue injury with greater hemodilution explained
earlier findings of improved neurological outcomes with
high hematocrit.2,3
Arguably, the above results may have significant impli-
cations to current CPB practice as they contradict prevailing
cardiac surgical dogma and current recommendations of
textbooks4,5, that is, that lower hematocrit values (20%)
minimize microcirculatory disturbances during CPB and
hence will improve tissue perfusion and oxygen delivery.
Additionally, if these findings in the cerebral microcircula-
tion prevail in other capillary beds, then milder hemodilu-
tion may similarly lead to improved post-CPB outcomes of
other vital organs.
In adult CPB, variations of body size and pre-CPB he-
matocrit, coupled with the essentially constant bypass cir-
cuit volume, inevitably lead to wide interpatient variability
of the nadir on-pump hematocrit.6 The primary objective of
this study was to elucidate the effects of varying “lowest
hematocrit” during CPB on postoperative organ dysfunction
and patient outcomes. We therefore determined in a large
contemporary cardiac surgery series (with CPB) the inci-
dence of serious complications, operative mortality, and
resource utilization in terms of varying lowest hematocrit.
Also, for isolated coronary artery bypass grafting (CABG),
we probed whether and how potential adverse effects of
lowest hematocrit levels alter long-term outcomes.
Methods
Patients
With approval of the St Vincent Mercy Medical Center (Toledo,
Ohio) Human Investigation Committee, we analyzed the clinical
outcomes of 5000 consecutive adult cardiac surgery patients from
a single institution (1994-2000). Standard CPB techniques were
applied with predominant (96%) use of normothermia (body tem-
perature: 35°C to 37°C).6 Arterial blood flow was determined on
the basis of a cardiac index of 2.5 to 3.0 (L · min1 · m2), and
mean arterial pressure was maintained at greater than 60 mm Hg.
All surgeons used standardized clinical care pathway protocols.
Data Collection
Risk factors, CPB variables, complications, and operative mortal-
ity (OM; in-hospital death or 30 days out-of-hospital death) data
were collected in a dedicated database. Cardiovascular intensive
care unit (CVICU) and postoperative length of stays (LOS) were
entered for all patients in the same database. Total direct variable
costs (Cost) were compiled for patients from 1997 to 2000, and
these encompassed every care-related expense throughout the ad-
mission period.7 Cost data are presented in terms of the annual
average cost to correct for inflation.
The social security death index database (http://ssdi.geneology.
rootsweb.com) was queried in October 2001 for each patient via
individual searches to verify accurate out-of-hospital death data.
This resulted in survival follow-up data for all patients ranging
from up to 8 to 93 months. Our database was updated for any
missing late mortality data.
Data Analysis/Statistical Methods
Univariate analyses. Lowest hematocrit is a continuous nor-
mally distributed variable, and examining its effects on “dichoto-
mous” outcome measures (eg, mortality [yes/no]) can hinge on
how the population is subdivided.6 Multiple steps were applied to
identify outcomes associated to the extent of hemodilution on
CPB. First, mean lowest hematocrit values of each complicated
subgroup (eg, stroke) were compared with patients free of any
complications. Next, incidence of each complication was com-
pared among lowest hematocrit quintile groups (n  1000 each).
Finally, we derived continuous independent variable–outcome re-
lations by consideration of rolling decile subgroups.6 Here, patient
data were first arranged in increasing lowest hematocrit order, and
a total of 37 subgroups (75% overlapping ranges) were separately
analyzed, such that group 1 included patients 1 to 500 (0%-10%),
group 2 included patients 126 to 625 (2.5%-12.5%), and so on.
Note, with this method, the smaller subgroup size minimized
within-group lowest hematocrit heterogeneity while the 75% over-
lap smoothed the effects of similar lowest hematocrit values in
consecutive subgroups.
Continuous variables were presented as mean  standard de-
viation and categorical data were presented as frequency counts
(N, %). Nonlinear regression analyses (SPSS, Inc, Chicago, Ill)
were used to describe continuous lowest hematocrit–outcome re-
lations. Group comparisons of continuous variables were done
using unpaired t test (2 groups) or 1-way analysis of variance (3 or
more groups) depending on applicability. 2-Square tests were
used for categorical variables. Long-term survival was assessed via
Kaplan-Meier and death hazard analyses.8
Multivariate analyses. We used multivariate analyses to de-
termine if and how nadir on-pump hematocrit, among other vari-
ables, predicted certain outcomes (length of stay as well as early
and late mortality). Also, we determined the pre- and intraopera-
tive variables predicting the extent of hemodilution on CPB, or
lowest hematocrit (%), via multiple linear regression analysis
(SPSS). All multivariate methods were limited to the 3800 patients
who underwent isolated CABG to avoid the possible varying
effects on outcomes of valve and or combined operations.
First, predictors of operative mortality and perioperative mor-
bidity were derived via multiple logistic regression (SPSS). We
defined perioperative morbidity as patients who remained in ex-
cess of 48 hours in cardiovascular intensive care (CVICU  2
days) or patients with postoperative hospital stays greater than 8
days. Cox proportional hazard models were used to define the
effect of explanatory variables (including lowest hematocrit) on 0-
to 6-year mortality after CABG with CPB. Model selection was
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first done with backward elimination and variables significant at
the P  .05 level were retained in the model as independent
predictors. Models were then confirmed using forward selection
and stepwise selection. The considered prognostic variables in the
multivariate models were the preoperative and intraoperative vari-
ables listed in Table 1 in addition to the categorical variables
postoperative transfusion and use of intra-aortic balloon pump.
Results
This CPB series (64 11 years) included 3296 (66%) men
and 1704 (34%) women (Table 1). Of these, 3800 under-
went isolated CABG (76%). The lowest hematocrit value
reached during CPB varied widely among patients (21.4 
4.2%, median  21.2%, range: 9.1%-40.3%). Lowest he-
matocrit quintiles show that older age, female sex, diabetes,
history of cerebrovascular accidents, preoperative renal fail-
ure, peripheral vascular disease, non-CABG, reoperation,
nonelective status, and increased time on bypass were all
more frequent in more hemodiluted patients (Table 1). Al-
ternatively, ejection fraction, chronic obstructive pulmonary
disease, left main disease, and three-vessel disease did not
vary with this on-pump hematocrit level.
Independent predictors of the nadir hematocrit deter-
mined via multivariate linear regression included four con-
tinuous (pre-CPB hematocrit value, body surface area, time
on CPB, and age) and two categorical (female sex and
preoperative renal failure) variables (Table 2). Pre-CPB
hematocrit value (%) and body surface area (BSA) were the
main determinants of the nadir hematocrit on pump as
would be expected based on red blood cell mass balance
considerations in conjunction with a constant volume of the
CPB crystalloid prime. Alternatively the variations in low-
est hematocrit value in terms of age and time on CPB are
probably indirect, and reflect (1) the on-average lower pre-
CPB hematocrit value (39%-35%) and BSA (2.0-1.8 m2)
with increasing CABG patient age (60-80 years) and (2)
greater blood loss with prolonged pump times.
A total of 181 operative deaths (3.6%) patients were
documented in this 5000 CPB patient series, and 975 pa-
TABLE 2. Predictors of lowest hematocrit (%) during CPB
derived by forward stepwise multivariate linear regression
Variable
Coefficient
(a1–a6) Std Error P value R R
2 (%)
Pre-CPB Hct (%) 0.390 0.010 .001 0.660 73.4
BSA (m2) 5.467 0.235 .001 0.740 18.9
Time on CPB (min) 0.022 0.001 .001 0.760 5.1
Female 1.327 0.115 .001 0.769 2.3
Age (years) 0.017 0.004 .001 0.770 0.3
Renal failure 0.825 0.268 .002 0.771 0.2
Model: lowest hematocrit (%)  a1*Pre-CPB Hct (%)  a2*BSA (m
2) 
a3*Time on CPB (min)  a4*Female  a5*Age (years)  a6*renal failure.
Model passed normality (P  .89) and constant variance (P  .012) tests;
power (  0.05)  1.0; female and renal failure are categorical variables
where yes  1 and no  0.
TABLE 1. Demographics, risk factors, and cardiopulmonary bypass data for all patients and for quintiles (I–V) divided
based on lowest hematocrit
Category
All patients Lowest hematocrit subgroups* (No.  1000)
P valueMean  SD/n % I II III IV V
Females 1704 34.0 70.3 50.0 29.6 15 4.4 .001
Age (years) 64  11 67  11 66  11 65  11 63  10 60  11 .001
Body surface area (m2) 1.96  0.23 1.79  0.19 1.89  0.20 1.96  0.19 2.04  0.19 2.13  0.19 .001
Diabetes 1562 31.2 35.6 34.6 29.8 27.6 28.6 .001
Renal failure 171 3.4 8.0 4.6 2.3 1.6 0.6 .001
Cerebrovascular accident 416 8.3 11.1 9.3 8.6 6.1 6.5 .001
COPD 1110 22.3 22.6 22.0 22.5 22.2 22.2 NS
Peripheral vascular disease 839 16.8 21.2 19.4 16.3 15.4 11.6 .001
Left main disease 895 18.2 19.5 19.1 17.4 16.8 18.0 NS
Three vessel disease 3173 63.4 61.2 62.4 63.5 65.5 64.2 NS
Ejection fraction (%) 49  12 50  12 49  12 50  12 49  12 49  11 NS
Isolated CABG 3800 76.0 67 72 76.9 78.9 84.6 .001
Redo Surgery 345 7.2 8.8 8.8 6.6 8.1 3.6 .001
Nonelective 2807 56.1 62.5 57.6 53.2 51.6 55.7 .001
Time on CPB (min) 95  47 106  59 98  51 93  44 91  39 85  36 .001
Pre-CPB hematocrit (%) 37.8  5.4 32.9  4.4 35.4  4.4 38.0  4.1 40.1  4.2 42.6  3.7 .001
Lowest hematocrit (%) 21.4  4.2 15.9  1.4 18.9  0.7 21.3  0.7 23.6  0.8 27.5  2.1 .001
Post-CPB hematocrit (%) 23.5  4.2 19.7  3.4 21.1  2.7 22.8  2.8 25.1  1.9 29  2.6 .001
Intraoperative transfusion 1305 26.1 66.6 32.8 17.1 10.3 3.6 .001
*Quintile data presented either as mean  SD (standard deviation) or as % incidence. Statistical comparisons were done using one-way analysis of
variance or Chi-square test as applicable. CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; n  number of patients
or frequency; NS  differences between quintile groups are not significant.
Habib et al Cardiopulmonary Support and Physiology
1440 The Journal of Thoracic and Cardiovascular Surgery ● June 2003
CPS
tients had at least one postoperative complication (19.5%).
For the 3800 CABG only patients in this series, as of
October 2001, 355 (9.3%) patients were dead (OM: 90 or
2.4%; late: 265 or 6.9%). Time to death was 20 21
months (median  10; range: 0-79) and follow-up was
53 23 (median  53, range: 8-93) months.
Effects of Lowest Hematocrit on Outcomes
Operative outcomes. Variations in hemodilution levels
for patients, which were divided based on incidence of
postoperative complications, are summarized in Table 3.
Lowest hematocrit for OM (19.0  4.1%) and complicated
(19.9  4.0%) patients were significantly lower than for
uncomplicated (21.8  4.1%) patients (unpaired t test).
Moreover, this trend was true for all types of complications,
and more severe hemodilution was associated with greater
likelihood of multiple complications.
Consistent with the above, analysis of lowest hematocrit
based quintiles (Table 4) shows that all measures of mor-
bidity, except for sternal wound infection and acute respi-
ratory distress syndrome, change systematically with the
extent of hemodilution (1-way analysis of variance). In
brief, for all CPB as well as for isolated CABG (Figure 1),
the incidence of reoperation for bleeding (fivefold), tam-
ponade (sixfold), perioperative myocardial infarction
(fourfold), cardiac arrest (fourfold), permanent stroke
(sixfold), coma (sixfold), prolonged mechanical venti-
lation (threefold), pulmonary edema (fourfold), septice-
mia (threefold), use of intra-aortic balloon pump (four-
fold), renal failure (fourfold), and multiorgan failure
(sevenfold) were all systematically greater as lowest he-
matocrit value decreased. Note, adverse hemodilution ef-
fects were particularly greater for lowest hematocrit value
below 22%.
Consequently, CVICU/postoperative LOS and OM var-
ied substantially with lowest hematocrit value (Figure 2).
Both hospital stays and OM were generally lower for (1)
CABG versus non-CABG patients and (2) younger (65
years) versus older (65 years) patients. Yet, their decreas-
ing trends as lowest hematocrit increased were similar.
Multivariate predictors of operative mortality and morbidity
(CVICU  2 days, postoperative LOS  8 days) as deter-
mined by multivariate logistic regression are summarized in
Table 5. This analysis showed that, along with other pre-
dictors, decreased lowest hematocrit value (%; considered
as a continuous variable) is associated with (1) increased
operative mortality (risk ratio: 0.863; P  .001), (2) in-
creased likelihood of prolonged intensive care stay (CVICU
 2 days; risk ratio: 0.968; P  .001), and (3) greater
likelihood of postoperative hospitalization of 9 or more days
(postoperative LOS 8 days; risk ratio: 0.954; P  .001).
Frequency of intraoperative and postoperative transfu-
sion and the direct variable costs of surgery were strongly
related to the severity of hemodilution (Figure 3). Note, the
effects of hemodilution on average operative costs were
similar for all CPB surgeries or CABG only, and these
increased sharply for lowest hematocrit  20%, while they
were unchanged for lowest hematocrit value 24%.
Longer-term outcomes. For all isolated CABG patients
combined, the 1-, 3-, and 6-year survival estimates were
95.2%, 92.5%, and 88.1%, respectively. However, longer-
term (0-6 years) effects of decreased lowest hematocrit
value were also apparent in isolated CABG patients. When
separately analyzed, lowest hematocrit value (16.1%-
27.5%) CABG quintiles (760 patients each) exhibited in-
creasingly better survival (1-year: 90.1%-97.6%; 3-year:
86.1%-96.0%; and 6-year: 80.5%-92.3%) with decreasing
hemodilution severity (Figure 4, top). Moreover, death haz-
ard analysis of the Kaplan-Meier survival curves for CABG
patients divided to lowest hematocrit 20% (N  1418)
versus 20% (N  2382) shows systematically greater
TABLE 3. Variations in lowest hematocrit on CPB for com-
plicated patient groups
Patient group
Mean 
SD Median P value
All patients 21.4 4.2 21.2
Operative mortality 19.0 4.1 18.5 .001
Postop complication
No (4025; 80.5%) 21.8 4.1 21.8 Ref.
Yes (975; 19.5%) 19.9 3.9 19.4 .001
One (451; 9.0%) 20.4 3.7 20.0 .001
Two (251; 5.0%) 19.7 4.0 19.1 .001
Three or more (273; 5.5%) 19.4 4.0 19.1 .001
Reoperation for bleeding 19.5 3.9 19.1 .001
Infection 20.3 3.9 19.7 .001
Sternal wound infection 20.8 3.6 20.0 .07
Septicemia 20.0 4.0 19.4 .001
Neurologic 19.6 4.0 19.1 .001
Transient stroke 20.2 3.8 20.0 .001
Permanent stroke 19.2 4.1 18.8 .001
Coma 18.9 3.2 18.8 .001
Pulmonary 19.7 4.0 19.1 .001
Prolonged ventilation 19.6 4.0 19.1 .001
Pulmonary edema 19.4 3.7 19.1 .001
ARDS 20.3 3.9 20.6 .02
Cardiac 19.5 4.0 19.1 .001
Perioperative MI 19.5 4.2 19.4 .001
Tamponade 19.3 3.5 19.4 .001
Cardiac arrest 19.2 4.1 18.5 .001
Intra/postop IABP 19.5 4.0 18.8 .001
Renal failure 19.9 3.8 19.7 .001
Multiorgan failure 19.2 3.9 18.5 .001
All statistical comparisons of lowest hematocrit (%) for the various com-
plication/mortality subpopulations were done using the unpaired t test
where the patients with no postop complications were used as the refer-
ence population (referred to as Ref. in the table). ARDS, acute respiratory
distress syndrome; IABP, intra-aortic balloon pump; MI, myocardial infarc-
tion; n number of patients with complication; Ref, reference or statistical
control; SD, standard deviation.
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early as well as late mortality in the more severely hemodi-
luted group (Figure 4, bottom).
Results of multivariate Cox proportional hazard model
analysis of 0- to 6-year mortality are summarized in Table
6. These showed that decreased lowest hematocrit value (%)
is associated with worse survival over this interval (odds
ratio: 0.950; P  .001). Other predictors of 0- to 6-year
mortality were older age (years), increased time on cardio-
pulmonary bypass (minutes), lower ejection fraction (%), in
addition to four other categorical (yes/no) variables/diag-
noses: preoperative renal failure, chronic lung disease, ce-
rebrovascular disease, and peripheral vascular disease.
Discussion
We demonstrated, via a large consecutive adult cardiac
surgery series, that adverse outcomes after CPB are system-
atically increased as a function of hemodilution severity.
Specifically, we showed that most major complications,
including stroke, myocardial infarction, low cardiac output
syndrome (intraoperative/postoperative intra-aortic balloon
pump), renal failure, pulmonary edema, reoperation due to
bleeding, sepsis, and multiorgan failure, are increased as the
nadir hematocrit during CPB decreased (Figure 1). More-
over, this hematocrit–complications association inevitably
resulted in significantly and systematically greater intensive
care requirements, hospital stays, operative costs, and death
with increasing levels of hemodilution, particularly for low-
est hematocrit value less than 22% (Figures 3 and 4).
Indeed, the observed-to-expected (O/E) CABG mortality
decreased systematically and substantially for patient co-
horts whose lowest hematocrit was between 15% and 22%
and was relatively unchanged for greater values (Figure 3,
bottom right). Lowest hematocrit value (%) was also found
to be an independent predictor of operative mortality and
morbidity (Table 5).
In addition, somewhat unexpectedly, we found that he-
modilutional anemia on bypass was associated with long-
term adverse effects as well. Specifically, survival trends of
lowest hematocrit CABG quintile subgroups (I to V: 760
patients each) were significantly and systematically better
with decreasing hemodilution severity (Figure 4). For ex-
ample, 6-year survival was 80.5% for group I patients in
whom the average lowest hematocrit value was a low
16.1%. In contrast, groups IV (lowest hematocrit value:
23.6%) and V (lowest hematocrit: 27.5%) both had a 92.3%
survival 6 years after CABG. Granted, systematically
younger age of patients for group I (67 years) through group
V (60 years) and the fact that operative deaths were also
greater in the more hemodiluted patients have contributed to
the difference in survival. However, this lowest hematocrit
effect on intermediate-term survival that is apparent from 0-
to 6-year survival and death hazard analyses in CABG
patients (Figure 4) was confirmed to be an independent
predictor by multivariate Cox proportional hazard analysis
(Table 6).
TABLE 4. Postoperative data for all patients and for quintiles (I–V) divided based on lowest hematocrit
Category
All patients Lowest hematocrit subgroups* (NQ  1000)
P valueMean  SD/n % I II III IV V
Postoperative transfusion 1691 33.8 55.7 46.0 32.0 23.0 12.3 .001
Reoperation for bleeding 145 2.9 5.1 3.6 3.0 1.6 1.2 .001
Sternal wound infection 69 1.4 1.5 2.0 1.4 1.1 0.9 NS
Septicemia 103 2.1 2.9 2.9 1.7 1.6 1.2 .02
Transient stroke 63 1.3 2.0 1.2 1.3 1.2 0.6 .09
Permanent stroke 95 1.9 3.4 2.5 1.2 1.7 0.7 .001
Coma 54 1.1 1.8 2.0 0.7 0.7 0.2 .001
Prolonged ventilation 450 9.0 15.3 12.1 6.6 6.4 4.6 .001
Pulmonary edema 138 2.8 4.8 4.4 1.9 1.6 1.1 .001
ARDS 52 1.0 1.4 1.1 0.8 1.2 0.7 NS
Perioperative MI 55 1.1 1.9 1.5 0.8 0.8 0.5 .02
Tamponade 42 0.8 1.3 1.3 1.0 0.3 0.3 .02
Cardiac arrest 163 3.3 6.2 4.6 1.7 2.5 1.3 .001
Intra/postoperative IABP 224 4.5 9.1 4.1 3.9 3.2 2.1 .001
Renal failure 294 5.9 7.9 8.5 5.7 4.9 2.4 .001
Multiorgan failure 93 1.9 3.4 2.8 1.1 1.3 0.7 .001
Operative mortality 181 3.6 7.5 4.7 1.8 2.5 1.6 .001
CVICU stay (days) 1.7 3.0 2.0 3.2 2.1 3.8 1.5 2.4 1.5 2.7 1.3 2.3 .001
Postoperative LOS (days) 7.6 9.1 9.5 11.1 8.6 10.8 7.7 9.8 6.5 6.6 6.0 5.6 .001
ARDS, Acute respiratory distress syndrome; CVICU, cardiovascular intensive care unit; IABP, intra-aortic balloon pump; LOS, length of stay; MI, myocardial
infarction; n, number of patients or frequency; NS, differences between quintile groups are not significant.
*Quintile data presented either as mean  SD (standard deviation) or as % incidence. Statistical comparisons were done using one-way analysis of
variance or Chi-square test as applicable.
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Figure 1. Incidence of 12 postoperative complications (see specific complication on each plot) reflecting the
dysfunction post-CPB of the various vital organs shown plotted in terms of increasing lowest hematocrit for all
cardiac surgeries (n  5000 patients). All types of complications were more frequent as hemodilution severity
increased, particularly for lowest hematocrit < 22%. Lines (solid and dashed) represent nonlinear regression
approximations of actual trends shown for rolling decile groups as symbols (open and closed, respectively). These
trends were similar (albeit not in magnitude) when only isolated CABG patients (n 3800) are considered (symbols
were omitted for clarity). Generally lower incidence of complications in CABG compared to all cardiac operations
suggest higher incidence of complications in non-CABG operations with perhaps greater adverse effects of
hemodilution.
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Other authors9-11 have suggested a possible link be-
tween hemodilution on CPB and worse operative out-
comes after CABG but, to our knowledge, no studies
have previously reported an association between CPB
hemodilution levels and worse longer-term outcomes.
Consistent with our data, DeFoe and colleagues9 reported
increased reoperation of bleeding and low cardiac output
and in-hospital mortality with increased hemodilution
severity. They, however, did not find a systematic in-
crease in stroke. Hardy and coworkers10 reported in-
creased postoperative renal failure, hemodynamic insta-
bility, and death with decreased hematocrit (1) on pump
or (2) during the first 24 hours postoperatively. Fang and
colleagues11 used a multivariate analysis that separated
low- and high-risk CABG patients and concluded that
hematocrit values below 14% in low-risk patients and
17% in high-risk patients are associated with a doubling
of the risk of death. A similar variance was also evident
by contrasting our LOS (hematocrit and mortality) he-
matocrit data for young (lower-risk) versus older (higher-
risk) patients (Figure 2). These showed that worse out-
comes occur at relatively lower hematocrit values
Figure 2. Top, CVICU and postoperative hospital stays were systematically and significantly decreased between
low (15%) and high (29%) lowest hematocrit overlapping decile groups for all CPB patients (left) and for isolated
CABG (right). Bottom, Operative mortality (OM) was systematically and significantly decreased between low (15%)
and high (29%) lowest hematocrit overlapping decile groups for all CPB patients (left) and for isolated CABG (right).
Although OM is lower in young (dashed, thin lines) compared with older (dashed, thick lines) patients, the relative
trends of increased deaths with severity of hemodilution were comparable (lowest hematocrit < 20%) irrespective
of age. Bottom right (inset), Observed-to-expected (O/E) mortality decreased systematically and substantially for
patient cohorts whose lowest hematocrit value was between 15% and 22% and was relatively unchanged for
greater values. Expected mortality was derived from patient data using The Society of Thoracic Surgeons CABG
multivariate operative risk model.23. Lines represent nonlinear regression approximations of actual trends shown
for rolling decile groups as symbols. These trends were similar in young (dashed, thin lines) and old (dashed, thick
lines) patients. Symbols for age subgroups were omitted for clarity.
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in young (20%) compared with older (22% to 24%)
patients indicating a varying tolerance of hemodilution
on CPB.
In this series, we report associations between hemodilu-
tion levels and a large number of complications, as well as
a number of morbidity and mortality measures. An obvious
reason for this is that more outcome variables were included
in the analysis. We also contend that this was facilitated by
the consideration of lowest hematocrit as a continuous vari-
able as opposed to use of arbitrary hematocrit values to
define patient cohorts. Also, via the overlapping deciles
analyses one is able to better define the continuous relations
between on-pump hemodilutional anemia and specific post-
operative complications, resource use, and death.
Roach and colleagues12 recently reported that adverse
neurologic events of varying severity are unfortunately
TABLE 5. Predictors of operative mortality and morbidity after CABG by multivariate logistic regression analysis
Outcome/variable B SE
Wald
statistic P value OR
95% CI
Lower Upper
Operative mortality
Lowest hematocrit (%) 0.147 0.030 24.595 .001 0.863 0.815 0.915
Age (years) 0.046 0.010 23.410 .001 1.047 1.028 1.067
Time on CPB (min) 0.015 0.002 43.458 .001 1.015 1.011 1.020
Ejection fraction (%) 0.037 0.009 16.210 .001 0.964 0.947 0.981
Renal failure 1.487 0.362 16.871 .001 4.425 2.174 9.010
Redo CABG 0.909 0.339 7.206 .007 2.481 1.279 4.831
Chronic lung disease 0.844 0.258 10.687 .001 2.326 1.403 3.861
Cerebrovascular disease 0.637 0.252 6.405 .011 1.890 1.155 3.096
Peripheral vascular disease 0.623 0.265 5.514 .019 1.866 1.109 3.135
CVICU > 2 days
Lowest hematocrit (%) 0.084 0.017 27.757 .001 0.968 0.957 0.980
Age (years) 0.019 0.006 10.687 .001 1.019 1.008 1.031
Time on CPB (min) 0.013 0.002 39.366 .001 1.013 1.009 1.017
Ejection fraction (%) 0.031 0.006 24.359 .001 0.970 0.958 0.982
Renal failure 1.709 0.304 31.506 .001 5.525 3.040 10.00
Elective 0.782 0.181 18.640 .001 0.458 0.321 0.653
Peripheral vascular disease 0.504 0.188 7.176 .007 1.656 1.145 2.392
Postop LOS > 8 days
Lowest hematocrit (%) 0.047 0.011 16.908 .001 0.954 0.933 0.976
Age (years) 0.040 0.004 89.386 .001 1.041 1.032 1.049
Time on CPB (min) 0.004 0.001 10.116 .001 1.004 1.002 1.007
Renal failure 1.456 0.226 41.380 .001 4.292 2.755 6.667
Chronic lung disease 0.497 0.117 18.051 .001 1.642 1.307 2.066
Cerebrovascular disease 0.278 0.112 20.753 .013 1.321 1.060 1.645
Peripheral vascular disease 0.421 0.127 10.925 .001 1.524 1.188 1.957
Ejection fraction (%) 0.017 0.004 41.380 .001 0.983 0.975 0.991
Redo CABG 0.959 0.185 26.835 .001 2.611 1.815 3.745
Elective 0.327 0.109 9.003 .003 0.721 0.582 0.893
OR, Odds ratio; CI, confidence interval; SE, standard error; B, coefficient in multivariate model.
TABLE 6. Predictors of 0- to 6-year mortality after CABG by multivariate Cox proportional hazard model analysis
Variable B SE
Wald
statistic P value
Risk
ratio
95% CI
Lower Upper
Lowest hematocrit (%) 0.051 0.016 10.682 0.001 0.95 0.921 0.980
Age (years) 0.049 0.007 53.24 0.001 1.05 1.036 1.064
Time on CPB (min) 0.011 0.001 66.37 0.001 1.011 1.008 1.014
Ejection fraction (%) 0.012 0.005 6.823 0.009 0.988 0.979 0.997
Renal failure 1.279 0.197 42.129 0.001 3.597 2.439 5.291
Chronic lung disease 0.383 0.132 8.466 0.004 1.466 1.134 1.901
Cerebrovascular disease 0.593 0.13 20.753 0.001 1.808 1.403 2.336
Peripheral vascular 0.288 0.122 5.54 0.019 1.333 1.049 1.695
Disease
CI, Confidence interval; SE, standard error; B, coefficient in multivariate model.
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among the most frequent complications of CPB. Moreover,
Newman and coworkers13 showed a relatively high preva-
lence and persistence of neurocognitive deficits after
CABG. To our knowledge, the substantial dependence of
the incidence of stroke on lowest hematocrit is the first such
reported association in adult cardiac surgery. This perhaps
implicates hemodilution severity as a primary cause of CPB
adverse neurologic effects. Importantly, this agrees with
experimental findings of reduced cerebral oxygen deliv-
ery1,14-19 and worse neurologic outcomes2,3 with low he-
matocrit on CPB. Indeed, in case of normothermic CPB,
Liam and colleagues19 showed using a dog model that both
oxygen delivery and whole body oxygen uptake were re-
duced when hematocrit values fell below 25%, becoming
significant at 18% or below. They further concluded that (1)
hematocrit levels above 18% were needed to maintain ox-
ygen delivery and consumption, (2) the critical hematocrit
value may be higher for bypass compared with nonbypass
hemodilution states, and (3) the critical hematocrit value for
the body appears to be higher than that required for the brain
during warm bypass, presumably because the brain is more
effective at increasing its flow in hemodiluted states. Inter-
estingly, the experimental data of Liam and colleagues19
agrees with our clinical data, which showed little or no
adverse effects of hemodilution when hematocrit values did
not fall below the 21% to 22% levels (Figure 2). This
critical hematocrit falls within the 25% and 18% hematocrit
values identified by them for adequate versus compromised
oxygenation, respectively.
A number of large studies have convincingly shown that
small size and female (who are small relative to males)
patients have worse outcomes of CPB including greater
OM.6,9,10,20-22 We believe that the poor outcomes in these
two patient subpopulations are directly linked to their rela-
tively more severe hemodilution during CPB. In this series,
OM was significantly greater in female and low-BSA pa-
tient subpopulations, both of which were characterized by
significantly (P  .001) lower nadir hematocrit values on
pump: (1) female compared with male patients [OM: 3.3%
(39/1175), lowest hematocrit: 18.7  3.9% vs 1.9% (51/
2625), 23.1  3.1%] and (2) small-size (BSA  1.8 m2)
compared with larger-size (BSA  1.8 m2) patients [3.9%
(33/846), 18.4  3.2% vs 1.9% (57/2954), 22.7  3.9%].
Prolonged time on cardiopulmonary bypass (100 min-
utes) and increased age are also established major determi-
nants of increased morbidity and mortality after CABG,23 a
fact confirmed in this series as well. In addition, we have
found that severity of hemodilution during cardiopulmonary
bypass as defined by the nadir on-pump hematocrit is a
strong predictor of increased CABG morbidity (Figures 3
Figure 3. Right, Cost of cardiac surgery was systematically and significantly decreased between low (15%) and
high (29%) lowest hematocrit overlapping decile groups for all CPB patients (circles) and for isolated CABG
(triangles). Lines represent nonlinear regression approximations of actual trends shown for rolling decile groups
as symbols. Left, Incidence of transfusion (any, intraoperative, postoperative, and both intraoperative and postop-
erative) decreased substantially and systematically as a function of hemodilution on pump in cardiac surgery
patients, as illustrated for overlapping decile cohorts (500 patients each) from low (15%) to high (29%) lowest
hematocrit value during CPB. Compared with nontransfused patients (23.2  3.7 [23.2%]), mean (median) lowest
hematocrit values were substantially lower for transfused patients (any: 19.2  3.5 [18.8%]; intraoperative: 18.0 
3.2 [17.6%]; postoperative: 19.5  3.6 [19.1%]; both: 17.9  3.2 [17.4%]; all with P < .001 [unpaired t test]).
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and 4, Table 5) and mortality (Figure 2, Table 5). Yet, the
extent to which hemodilution severity alters observed op-
erative outcomes in relation to patient age and duration of
bypass is not known. We thus compared the incidence of
OM and postoperative hospital stays (POLOS) in (1) age
and (2) time on CPB patient decile groups (380 patients
each). Here, within each decile group, OM and POLOS
were contrasted for patients whose nadir hematocrit
dropped to 21% or less versus those with lowest hematocrit
values greater than 21% (Figure 5). Irrespective of age and
duration of CPB, we found substantial and systematically
increased poorer outcomes (OM and POLOS) in the more
hemodiluted patients. Moreover, this hemodilution effect on
OM tended to be greater in patients who are over 70 years
and/or those who remained on bypass for 2 or more hours.
Although it remains to be proven by prospective studies,
these findings do suggest that the possibility of improved
operative outcomes if hemodilution to levels below 21% is
avoided during CPB and that older patients and prolonged
cardiopulmonary bypass patients might benefit most from
such control of on-pump hematocrit levels. Finally, the
tendency of greater OM variance with hematocrit value with
Figure 4. Top, Kaplan-Meier 0- to 6-year survival plots shown for all five CABG lowest hematocrit quintile groups
(I to V: n  760 each). Compared with quintile V (least hemodiluted), survival for quintiles I (P < .001), II (P < .001),
and III (P  .002) was significantly worse by log-rank test. Bottom, Comparison of early and late mortality in CABG
patients hemodiluted down to 20% or less versus those with lowest hematocrit values >20% as derived by death
hazard analysis. Corresponding survival plots (which are implicit from top panel data) are not shown.
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longer pump runs is suggestive of a dose effect of on-pump
hemodilution (ie, adverse effects of the same low [21%]
nadir hematocrit may be increased as the duration of bypass
increases).
If the aforementioned associations between low hemat-
ocrit levels on CPB and worse outcomes obtained by the
reported univariate and multivariate analyses are shown to
be causal by prospective randomized studies, then methods
aimed at minimizing on-pump hemodilutional anemia (eg,
lowest hematocrit  22%) might lead to significant im-
provements in patients at risk. Note, hematocrit value dur-
ing CPB is an intraoperative variable that cardiac surgeons
can potentially control so that adverse outcomes are mini-
mized in contrast to preoperative variables over which they
have little or no control and, ironically, these have been
traditionally the focus of quality improvement.
Hemodilution during CPB results from the mixing of
pump crystalloid and colloid prime solution with the pa-
tient’s blood, and these two relative volumes, along with
pre-CPB hematocrit, will largely determine the nadir he-
matocrit (Table 2). In that sense, lowest hematocrit value
during CPB is then a potentially modifiable risk factor.
Figure 5. Analysis of the interaction between the effects of lowest hematocrit (symbols) and two important
covariate predictors (time on CPB [minutes] and [b] age [years]) of operative mortality (OM) and morbidity
represented by postoperative length of hospital stays (postop LOS). Solid regression lines were used to delineate
the changes in OM and postoperative LOS in terms of the predictor variables time on CPB and age for all patients
irrespective of hemodilution levels (symbols were not used for visual clarity). Dashed lines in top panels represent
regression results describing the (1) OM–time on CPB and (2) OM–age relations for the two hemodilution
subgroups. See text for more details.
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Changes to several areas of practice in CPB patients can
alter the extent of hemodilution experienced in a given
patient. These include controlling preoperative blood loss
during routine phlebotomy and cardiac catheterization; pos-
sible redesign and use of variable-size, or multiple sizes of,
CPB circuits to be used according to patient BSA; minimiz-
ing of the tubing size (length and diameter) connecting the
patient and pump; more timely return of collected cells to
the circulating volumes; more strict control of intraoperative
blood loss and fluid administration; use of retrograde autol-
ogous priming of the CPB circuit, which has been shown to
reduce hemodilution and transfusion requirements24,25; and,
lastly, freer use of blood transfusions during CPB so as to
maintain hematocrit at predetermined levels. The latter is
perhaps the most controversial of the above recommenda-
tions. Yet, as Figure 3 shows, a large fraction of the more
hemodiluted patients are transfused anyway. Moreover, at a
minimum, our data raises the prospect that adverse transfu-
sion effects in CPB patients derive, in a significant way,
from the associated on-pump hemodilution as opposed to
being a consequence of transfusion per se. Obviously, this
question will only be resolved by appropriate prospective
studies.
In conclusion, we found strong systematic associations
between severity of hemodilution on CPB and serious com-
plications affecting most major vital organs; particularly
when the nadir hematocrit drops below 22%. Expectedly,
these associations then lead to (1) increased resource utili-
zation such as CVICU/hospital stays and operative costs
and, more importantly, (2) substantially greater operative
mortality. We also found evidence of potential long-term
effects of on-pump hemodilutional injury to vital organs as
manifested by the worse 0- to 6-year survival due to a
sustained increase in death hazard after CPB in the more
severely hemodiluted patients. We believe these data rep-
resent compelling evidence of substantially greater adverse
outcomes when hematocrit value during CPB is allowed to
fall below a critical value (22%) and hence warrant future
prospective confirmatory investigation that should also aim
to separate the correlated effects of substantial hemodilution
on bypass and transfusion of blood products. We further
speculate that these adverse effects might have as common
mechanisms (1) ischemic vital organ tissue injury within
vital organs due to inadequate oxygen delivery at low he-
matocrits, and (2) systemic inflammatory injury due to
increased white cell–endothelial activation in microcircula-
tory beds of vital organs. These hemodilution effects during
CPB per se have been convincingly demonstrated in recent
experimental studies by the Boston group1-3 and by Cook,
Daly, and coworkers.14-16,19
We thank Mike Evans and Sue Harvan (perfusionists) for their
valuable assistance in collection of the cardiopulmonary bypass
data.
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